[1] Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis, 1967; 20, 511-24. doi:  10.1016/0021-9681(67)90082-3
[2] Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63, 2935-59. doi:  10.1016/j.jacc.2013.11.005
[3] Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA, 2004; 291, 2591-9. doi:  10.1001/jama.291.21.2591
[4] Yang X, Li J, Hu D, et al. Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population:The China-PAR Project (Prediction for ASCVD Risk in China). Circulation, 2016; 134, 1430-40. doi:  10.1161/CIRCULATIONAHA.116.022367
[5] Zhang M, Jiang Y, Wang LM, et al. Prediction of 10-year Atherosclerotic Cardiovascular Disease Risk among Adults Aged 40-79 Years in China:a Nationally Representative Survey. Biomed Environ Sci, 2017; 30, 244-54.
[6] WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet, 2004; 363, 157-63. doi:  10.1016/S0140-6736(03)15268-3
[7] American Diabetes Association. Standards of Medical Care in Diabetes-2018. Diabetes Care, 2018; 41, S144-51. doi:  10.2337/dc18-S014
[8] Liu XZ, Gao Y, Fan J, et al. Metabolic abnormalities in rheumatoid arthritis patients with comorbid diabetes mellitus. Clin Rheumatol, 2018; 37, 219-26. doi:  10.1007/s10067-017-3847-7
[9] Li HH, Fan J, Huang S, et al. The prevalence of obesity and metabolic abnormalities in eastern China: A cross-sectional study. Int J Diabetes Dev Ctries, 2019 Feb 20.[Epub ahead of print]
[10] Johansson HE, Wåhlén A, Aldenbäck E, et al. Platelet Counts and Liver Enzymes After Gastric Bypass Surgery. Obes Surg, 2018; 28, 1526-31. doi:  10.1007/s11695-017-3035-5
[11] Guerra-Silva NM, Santucci FS, Moreira RC, et al. Coronary disease risk assessment in men:Comparison between ASCVD Risk versus Framingham. Int J Cardiol, 2017; 228, 481-7. doi:  10.1016/j.ijcard.2016.11.102
[12] Yang XL, Chen JC, Li JX, et al. Risk stratification of atherosclerotic cardiovascular disease in Chinese adults. Chronic Dis Transl Med, 2016; 2, 102-9. doi:  10.1016/j.cdtm.2016.10.001
[13] Winham SJ, de Andrade M, Miller VM. Genetics of cardiovascular disease:Importance of sex and ethnicity. Atherosclerosis, 2015; 241, 219-28. doi:  10.1016/j.atherosclerosis.2015.03.021
[14] Sun C, Xu F, Liu X, et al. Comparison of validation and application on various cardiovascular disease mortality risk prediction models in Chinese rural population. Sci Rep, 2017; 7, 43227. doi:  10.1038/srep43227
[15] Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol, 2018; 14, 185-201. http://www.nature.com/articles/nrneph.2017.189
[16] Bray GA, Smith SR, de Jonge L, et al. Effect of dietary protein content on weight gain, energy expenditure, and body composition during overeating:a randomized controlled trial. JAMA, 2012; 307, 47-55. doi:  10.1001/jama.2011.1918
[17] Paniagua L, Lohsoonthorn V, Lertmaharit S, et al. Comparison of waist circumference, body mass index, percent body fat and other measure of adiposity in identifying cardiovascular disease risks among Thai adults. Obes Res Clin Pract, 2008; 2, I-Ⅱ. doi:  10.1016/S1871-403X(08)00009-4
[18] Ouyang X, Lou Q, Gu L, et al. Anthropometric parameters and their associations with cardio-metabolic risk in Chinese working population. Diabetol Metab Syndr, 2015; 7, 37. doi:  10.1186/s13098-015-0032-5
[19] Schneider HJ, Glaesmer H, Klotsche J, et al. Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. J Clin Endocrinol Metab, 2007; 92, 589-94. doi:  10.1210/jc.2006-0254
[20] Caan B, Armstrong MA, Selby JV, et al. Changes in measurements of body fat distribution accompanying weight change. Int J Obes Relat Metab Disord, 1994; 18, 397-404. http://eurheartj.oxfordjournals.org/lookup/external-ref?access_num=8081431&link_type=MED&atom=%2Fehj%2F28%2F7%2F850.atom
[21] Shao J, Yu L, Shen X, et al. Waist-to-height ratio, an optimal predictor for obesity and metabolic syndrome in Chinese adults. J Nutr Health Aging, 2010; 14, 782-5. doi:  10.1007/s12603-010-0106-x
[22] Ashwell M, Gibson S. Waist to height ratio is a simple and effective obesity screening tool for cardiovascular risk factors:Analysis of data from the British National Diet And Nutrition Survey of adults aged 19-64 years. Obes Facts, 2009; 2, 97-103. doi:  10.1159/000203363
[23] Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors:systematic review and meta-analysis. Obes Rev, 2012; 13, 275-86. doi:  10.1111/j.1467-789X.2011.00952.x
[24] Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes:0.5 could be a suitable global boundary value. Nutr Res Rev, 2010; 23, 247-69. doi:  10.1017/S0954422410000144
[25] Parish S, Offer A, Clarke R, et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation, 2012; 125, 2469-78. doi:  10.1161/CIRCULATIONAHA.111.073684
[26] Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease:10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation, 2007; 115, 450-8. doi:  10.1161/CIRCULATIONAHA.106.637793
[27] Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007; 298, 309-16. doi:  10.1001/jama.298.3.309
[28] Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes:a systematic review and meta-analysis. Lancet, 2010; 375, 1875-84. doi:  10.1016/S0140-6736(10)60656-3
[29] Würtz P, Kangas A, Soininen P, et al. Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease:a note on Mendelian randomization studies. J Am Coll Cardiol, 2013; 62, 1906-8. doi:  10.1016/j.jacc.2013.07.085
[30] Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA, 2005; 294, 326-33. doi:  10.1001/jama.294.3.326
[31] Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016; 37, 2999-3058. doi:  10.1093/eurheartj/ehw272
[32] McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study):a case-control study. Lancet, 2008; 372, 224-33. doi:  10.1016/S0140-6736(08)61076-4
[33] Elshazly MB, Quispe R, Michos ED, et al. Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol:The Very Large Database of Lipids Study (VLDL-2B). Circulation, 2015; 132, 667-76. doi:  10.1161/CIRCULATIONAHA.115.016163
[34] Borghi C, Rodriguez-Artalejo F, De Backer G, et al. Serum uric acid levels are associated with cardiovascular risk score:A post hoc analysis of the EURIKA study. Int J Cardiol, 2018; 253, 167-73. doi:  10.1016/j.ijcard.2017.10.045
[35] Li X, Meng X, Timofeeva M, et al. Serum uric acid levels and multiple health outcomes:umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ, 2017; 357, j2376. http://www.bmj.com/content/357/bmj.j2376
[36] Liu XZ, Li HH, Huang S, et al. Association between hyperuricemia and nontraditional adiposity indices. Clin Rheumatol, 2018 Nov 29.[Epub ahead of print]
[37] Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta, 2018; 484, 150-63. doi:  10.1016/j.cca.2018.05.046